TipRanks
Advertisement
Advertisement

DE:7V3 Stock Latest News

Cantargia Preclinical Data Back Nadunolimab–RAS Inhibitor Combo in Aggressive Pancreatic Cancer
Company AnnouncementsCantargia Preclinical Data Back Nadunolimab–RAS Inhibitor Combo in Aggressive Pancreatic Cancer
7d ago
Cantargia Ramps Up Investor Outreach with Series of September Conferences
PremiumCompany Announcements
Cantargia Ramps Up Investor Outreach with Series of September Conferences
1M ago
Cantargia Maintains Buy Rating as Strategic Focus and Upcoming Nadunolimab Catalysts Offset Cut in Price Target to SEK12
PremiumRatings
Cantargia Maintains Buy Rating as Strategic Focus and Upcoming Nadunolimab Catalysts Offset Cut in Price Target to SEK12
2M ago
Cantargia details pipeline and financials in H1 2026 interim report
PremiumCompany Announcements
Cantargia details pipeline and financials in H1 2026 interim report
2M ago
7V3 Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
7V3 Earnings Report this Week: Is It a Buy, Ahead of Earnings?
2M ago
Cantargia schedules Q2 2026 results release and investor conference call
PremiumCompany AnnouncementsCantargia schedules Q2 2026 results release and investor conference call
2M ago
Cantargia Expands Share Capital After Rights Issue Completion
Premium
Company Announcements
Cantargia Expands Share Capital After Rights Issue Completion
2M ago
Cantargia: Nadunolimab’s Complementary Role in PDAC Supports Maintained Buy Rating and Reaffirmed $14 Target
Premium
Ratings
Cantargia: Nadunolimab’s Complementary Role in PDAC Supports Maintained Buy Rating and Reaffirmed $14 Target
3M ago
Cantargia Data Strengthen IL1RAP and Nadunolimab Case in Pancreatic Cancer
PremiumCompany Announcements
Cantargia Data Strengthen IL1RAP and Nadunolimab Case in Pancreatic Cancer
3M ago
Cantargia Raises SEK 75 Million in Undersubscribed Rights Issue and Grants Warrants to Fenja Capital
PremiumCompany Announcements
Cantargia Raises SEK 75 Million in Undersubscribed Rights Issue and Grants Warrants to Fenja Capital
4M ago
Cantargia Highlights Nadunolimab’s Pancreatic Cancer Potential in Upcoming KOL Call
PremiumCompany Announcements
Cantargia Highlights Nadunolimab’s Pancreatic Cancer Potential in Upcoming KOL Call
4M ago
Cantargia: Buy Rating Reiterated on Nadunolimab Pipeline Progress and New Lung Nodule Trial; SEK14.00 Price Target Maintained
PremiumRatings
Cantargia: Buy Rating Reiterated on Nadunolimab Pipeline Progress and New Lung Nodule Trial; SEK14.00 Price Target Maintained
4M ago
Cantargia Launches Phase 2 Prevention Trial of Nadunolimab in High‑Risk Lung Cancer Patients
PremiumCompany AnnouncementsCantargia Launches Phase 2 Prevention Trial of Nadunolimab in High‑Risk Lung Cancer Patients
4M ago
Cantargia launches SEK 124m rights issue to fund antibody pipeline
Premium
Company Announcements
Cantargia launches SEK 124m rights issue to fund antibody pipeline
4M ago
Cantargia Raises Up to SEK 199 Million to Advance Nadunolimab Oncology Pipeline
Premium
Company Announcements
Cantargia Raises Up to SEK 199 Million to Advance Nadunolimab Oncology Pipeline
4M ago
Cantargia Raises Funds to Expand Nadunolimab Strategy in Cancer and Blood Disorders
PremiumCompany Announcements
Cantargia Raises Funds to Expand Nadunolimab Strategy in Cancer and Blood Disorders
4M ago
Cantargia: Buy Rating Reiterated on Strategic Pipeline Progress and Unchanged $14 Price Target
PremiumRatings
Cantargia: Buy Rating Reiterated on Strategic Pipeline Progress and Unchanged $14 Price Target
5M ago
Cantargia AGM Backs Equity Incentives and Expands Capital Raising Mandate
PremiumCompany Announcements
Cantargia AGM Backs Equity Incentives and Expands Capital Raising Mandate
5M ago
Cantargia Highlights Pipeline Progress in Q1 2026 Interim Report
PremiumCompany Announcements
Cantargia Highlights Pipeline Progress in Q1 2026 Interim Report
5M ago
Cantargia to Present Q1 2026 Interim Results in Audiocast and Teleconference
PremiumCompany AnnouncementsCantargia to Present Q1 2026 Interim Results in Audiocast and Teleconference
5M ago
Cantargia Reiterated as Buy on Nadunolimab’s Strong Early Data and Pipeline Progress; Price Target Maintained at SEK14
Premium
Ratings
Cantargia Reiterated as Buy on Nadunolimab’s Strong Early Data and Pipeline Progress; Price Target Maintained at SEK14
5M ago
Cantargia Reports Promising Early Remissions with Nadunolimab in High-Risk MDS and AML Trial
Premium
Company Announcements
Cantargia Reports Promising Early Remissions with Nadunolimab in High-Risk MDS and AML Trial
5M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >